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Background. Multiple sclerosis (MS), an inflammatory disease of the central nervous system, manifests itself in numerous
forms and stages. A number of brain metabolic alterations have been reported for MS patients vs. control subjects. However,
metabolite profiles of cerebrospinal fluid (CSF) are not consistent among the published MS studies, most probably due to
variations in the patient cohorts studied. We undertook the first investigation of highly homogeneous MS patient cohorts to
determine characteristic effects of inflammatory MS plaques on the CSF metabolome, including only patients with clinically
isolated syndrome (CIS) with or without inflammatory brain plaques, and controls. Methodology/Principal Findings. CSF
obtained by lumbar puncture was analyzed by proton magnetic resonance spectroscopy. 27 metabolites were quantified.
Differences between groups of control subjects (n=10), CIS patients with (n=21) and without (n=12) inflammatory plaques
were evaluated by univariate statistics and principal component analysis (PCA). Seven metabolites showed statistically
significant inter-group differences (p,0.05). Interestingly, a significant increase in b-hydroxyisobutyrate (BHIB) was detected in
CIS with vs. without active plaques, but not when comparing either CIS group with control subjects. Moreover, a significant
correlation was found, for the first time, between CSF lactate concentration and the number of inflammatory MS brain plaques.
In contrast, fructose concentrations were equally enhanced in CIS with or without active plaques. PCA based on all 27
metabolites yielded group-specific clusters. Conclusions/Significance. CSF metabolic profiles suggest a close link between
MS plaque activity in CIS patients on the one hand and organic-acid metabolism on the other. Our detection of increased BHIB
levels points to a hitherto unsuspected role for this compound in MS with active plaques, and serves as a basis for further
investigation. The metabolic effects described in our study are crucial elements in the explanation of biochemical mechanisms
involved in specific MS manifestations.
Citation: Lutz NW, Viola A, Malikova I, Confort-Gouny S, Audoin B, et al (2007) Inflammatory Multiple-Sclerosis Plaques Generate Characteristic
Metabolic Profiles in Cerebrospinal Fluid. PLoS ONE 2(7): e595. doi:10.1371/journal.pone.0000595
INTRODUCTION
Multiple sclerosis (MS) is a remarkably heterogeneous disease of
the central nervous system [1]. At present, numerous clinical and
biomedical studies are being carried out to characterize MS in its
various forms and stages, with the aim of elucidating the individual
mechanisms underlying their development and, ultimately,
exploring specific targets for effective treatment. Among other
methods, non-invasive in vivo
1H magnetic resonance spectrosco-
py (MRS) of the brain, as well as high-resolution MRS of
cerebrospinal fluid (CSF) have been employed to detect differences
in metabolic profiles between MS patients and controls. In vivo
1H
MRS of acute lesions revealed increased total MRS-visible choline
and lactate levels that tended to return to normal values after
several months [2]. Furthermore, transiently increased myo-
inositol (myo-Ins) and lipid MRS signals have been observed in
MS, followed by N-acetylaspartate decreases [2].
While in vivo biochemical analysis of the brain is limited to
a small number of metabolites, high-resolution
1H MRS of
biofluids enables one to quantitate a much larger range of
biochemical compounds, and thus to embark on a more detailed
analysis of metabolic mechanisms. We have previously reported
moderately increased CSF levels of lactate, creatinine, fructose and
an unidentified compound in MS vs. control patients, while
phenylalanine appeared to be decreased [3]. Our lactate findings
were in agreement with Simone et al. [4], but at variance with
other reports showing reduced lactate levels in CSF of MS patients
[5], or no lactate differences at all [6]. There are several potential
reasons for these discrepancies, besides differences in sample
handling. The possibility that confounding factors may in fact
determine the outcome of metabolomic analyses has recently been
acknowledged by a number of reports, including also studies
unrelated to neurological disease [7]. Since MS is a highly
heterogeneous disease, diverging data may simply reflect different
MS forms. Metabolic differences between CSF in relapsing-
remitting vs. primary-progressive MS have been systematically
investigated and were found to be negligible [3]. However, other
characteristics such as the stage of MS and the prevalence of
inflammatory vs. non-inflammatory plaques are rarely described
in detail in reports comparing CSF metabolic profiles of MS
patients to those of controls. To obtain more instructive results,
a comparative study under well controlled conditions was
required.
Increased lactate/creatine ratios have been found in CSF of MS
patients with inflammatory, Gd-DTPA (gadolinium diethylene-
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PLoS ONE | www.plosone.org 1 July 2007 | Issue 7 | e595triaminepentaacetate) contrast-enhanced (active) plaques at brain
MRI (magnetic resonance imaging) when compared to patients
without active plaques [4]. Since lactate is considered a marker of
acute inflammation, it was hypothesized that the increased
lactate/creatine ratios may reflect an increased CSF content of
lactate stemming from inflammatory plaques [4]. Indeed, the
presence of lactate, along with increases in total MRS-visible
choline and lipids, has been demonstrated in active MS plaques by
in vivo MRS [8]. The purpose of the present study was to
determine, for the first time, (i) specific metabolic differences
between MS with and without inflammatory plaques by
comparing absolute (molar) metabolite concentrations in CSF of
a highly homogeneous patient cohort, and (ii) the influence of
either MS manifestation on the metabolic profile of normal CSF.
Excellent patient group homogeneity was achieved by exclusively
analyzing, for the first time, CSF from patients at the first episode
(clinically isolated syndrome, CIS), and prior to glucocorticoid or
any other treatment. The role of gender and age as potential
confounding factors was also investigated. A better understanding
of the metabolisms underlying specific MS manifestations should
help develop tailored MS treatment protocols.
RESULTS
General characteristics of metabolite profiles
A total of 27 metabolites have been quantitated for CSF samples
from 11 control patients, 21 CIS patients with active MS plaques
(CIS group 1) and 12 CIS patients without active plaques (CIS
group 2). Essential patient characteristics are given in Table 1.
MRS signals used for quantitative evaluation were the most
prominent proton resonances of valine, leucine, isoleucine,
alanine, lactate, a-oxyisovalerate, a-hydroxyisovalerate, a-hydro-
xybutyrate, b-hydroxybutyrate, 1,2-propanediol, b-hydroxyisova-
lerate, b-hydroxyisobutyrate (BHIB), lysine, acetoacetate, acetate,
creatine, creatinine, pyruvate, glutamine, citrate, glucose, fructose,
myo-inositol, tyrosine, histidine, phenylalanine, formate, and three
minor N-acetyl compounds. Mean values6standard errors of the
means (s.e.m.) are given for concentrations of metabolites showing
significant differences between groups (Figure 1). Significant
differences are summarized in Table 2.
CSF metabolite concentrations cover a broad range of values
(Figures 2 and 3), with fructose varying between 0.10 and
0.45 mM (largest relative variation). Since the technical re-
producibility of metabolite quantitation lies within a few percent
for all but the least intense and/or strongly overlapping signals, the
variation within a group is clearly dominated by the biological
variability between subjects (standard deviations were about 15–
20% of the means). For most metabolites, concentration ranges
within the control group were equal to or somewhat larger than
the corresponding ranges for the individual CIS groups. Fructose
concentration ranges were an exception; they were considerably
broader for the CIS groups than for controls (Figure 2). In fact, the
differences in average fructose levels between either CIS group
and controls are the result of an extension of the range of CIS
fructose levels to higher values (.0.26 mM).
Inflammatory plaques alter BHIB, lactate and
phenylalanine CSF levels in CIS
Interestingly, b2hydroxyisobutyrate levels were significantly in-
creased in CIS group 1 vs. CIS group 2 (+27%; Figure 1, and
Tables 2 and 3). In addition, there was a trend (borderline
significance) for BHIB increase in CIS group 1 vs. controls
(Table 3). Moreover, lactate concentrations were moderately but
significantly increased for CIS group 1 vs. CIS group 2 (+13%;
Figure 1, and Tables 2 and 3), although the Kruskal-Wallis test did
not suggest an overall inter-group difference for lactate (p=0.154).
To explain this apparent contradiction, we analyzed the data
characteristics for CIS group 1 in more detail. Figure 3 shows
considerable clustering of lactate concentrations around 2.2 mM
Table 1. Patient characteristics.
......................................................................
Patient ID Sex Age number of active MS plaques in brain
1 F 32 1 CIS group 1
2 F 47 4
3 F 22 7
4 F 27 1
5 M 41 1
6 F 33 2
7 F 28 1
8 F 23 2
9 M 30 3
10 F 35 1
11 F 21 8
12 F 28 26
13 M 22 2
14 F 39 3
15 M 34 1
16 M 41 1
17 M 16 13
18 F 27 3
19 F 30 1
20 F 27 8
21 F 35 1
22 F 29 0 CIS group 2
23 F 28 0
24 M 39 0
25 F 32 0
26 F 48 0
27 F 42 0
28 M 24 0
29 F 32 0
30 F 23 0
31 F 25 0
32 F 49 0
33 M 33 0
34 F 36 0 controls
35 M 37 0
36 F 52 0
37 F 25 0
38 F 20 0
39 F 53 0
40 F 23 0
41 F 34 0
42 F 27 0
43 F 36 0
doi:10.1371/journal.pone.0000595.t001
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PLoS ONE | www.plosone.org 2 July 2007 | Issue 7 | e595for this group. Furthermore, Spearman rank analysis demonstrat-
ed a significant correlation between lactate levels and the number
of inflammatory plaques (tied p=0.0020, tied Rho=0.691). A
linear fit (Figure 4) resulted in a Y intercept (2.2260.04 mM for
a hypothetical number of zero active plaques) very close to the
mean value found for CIS group 2 presenting no inflammatory
plaques (2.1660.08 mM) (Figure 1). Thus, (i) lactate concentra-
tions in CIS group 1 cover a broad range of values depending on
the number of active plaques, and (ii) the power of the Kruskal-
Wallis test to detect lactate differences between groups is probably
compromised by the data overlap between all three groups, in
conjunction with major clustering at low lactate values in CIS
group 1. No correlations were found between lactate concentra-
tions in CSF and blood or urine (data not shown). For the
decreased phenylalanine levels found in CIS group 1 vs. CIS
group 2 (221%, Figure 1), both the Mann-Whitney U test and
Fisher’s PLSD (Protected Least Significant Difference) test yielded
a trend close to significance (Table 3).
CSF metabolite levels in CIS groups vs. controls
Comparisons of CSF metabolite levels for CIS group 2 and
controls yielded a statistically significant result solely for fructose
which was increased by 50% in CIS group 2 (Tables 2 and 3). A
somewhat smaller but equally significant fructose increase was
observed for CIS group 1 vs. controls (+46%). Thus, virtually all of
the CSF fructose increase in CIS patients vs. controls can be
ascribed to metabolic changes that occur irrespectively of the
presence of inflammatory MS plaques.
Differences between CIS group 1 and controls were significant
for fructose, acetate, glucose, and, to a lesser degree, glutamine
levels. These metabolites occurred at similar concentrations in CIS
groups 1 and 2 (no significant differences). In fact, both CIS
Figure 1. Selected CSF metabolite concentrations [mM] in patients with or without inflammatory brain MS plaques (abbreviated ‘inflamm’ and
‘non-infl’, respectively), and controls. Data represent means6s.e.m.
doi:10.1371/journal.pone.0000595.g001
Table 2. Significant differences between individual CIS groups
and controls.
......................................................................
lac phe BHIB gln fru ac crn b-glc
non-inflamm. vs.
control
X
inflamm. vs.
control
(X) XX Y X X
inflamm. vs. non-
inflamm.
X (Y) X
combined CIS vs.
control
XX Y X
Upward (downward) arrows indicate significantly increased (decreased) CSF
metabolite concentrations [mM] for CIS groups. The significance threshold was
set to p,0.05. Parametric multiple-comparison tests (Fisher’s PLSD) and
nonparametric Mann-Whitney U tests yielded consistent results with respect to
between-group significance (see Table 3). The arrow in parentheses indicates
a trend close to significance (0.05,p,0.10). Means6s.e.m. are given in Figure 1.
Abbreviations: lac, lactate; phe, phenylalanine; BHIB, b-hydroxyisobutyrate; gln,
glutamine; fru, fructose; ac, acetate; crn, creatinine; b-glc, b-glucose.
doi:10.1371/journal.pone.0000595.t002
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PLoS ONE | www.plosone.org 3 July 2007 | Issue 7 | e595manifestations changed each of these metabolite levels in the same
sense, compared to controls. However, CIS group 2 had smaller
effects (p.0.05) than CIS group 1, except for fructose where
effects were similar for both groups (Figure 1). Since both CIS
groups 1 and 2 changed these metabolite levels in the same sense,
significant differences were detected for fructose, acetate, glucose
and glutamine when pooled CIS values were compared to controls
(Table 2).
Principal component analysis (PCA) unambiguously showed
data clustering according to the three patient groups investigated.
Note that our PCA examination is based on true, absolute
metabolite concentrations rather than spectral points, and thus
directly reflects actual metabolite levels (see Materials and
Methods). Incomplete separation of data clouds, in particular for
the two CIS groups (Figures 5 and 6), suggests that while each
group is characterized by particular metabolic traits, these do
overlap to some degree.
Opposite trends for CIS with vs. without active
plaques
As opposed to the metabolites described in the previous
paragraph, no significant differences were detected for lactate
and BHIB when both CIS patient groups were pooled together
and compared to controls (Table 2). This is due to the fact that for
lactate and BHIB, CIS groups 1 and 2 produced opposite trends
(Figure 1): both metabolites were slightly reduced in CIS group 2
vs. controls (2.1660.08 vs. 2.2360.14 mM for lactate, and
0.01560.001 vs. 0.01660.001 mM for BHIB), but were increased
for CIS group 1 (2.4460.08 and 0.01960.001 mM for lactate and
BHIB, respectively). Consequently, these opposite trends compen-
sated each other when both CIS groups were combined into one
group. These opposite trends also explain why marked differences
were detected only when CIS groups were compared to each
other, but not when individual CIS groups were compared to
controls.
Correlations between metabolite levels and other
parameters
Besides counting the number of inflammatory MS plaques which
represent localized inflammation, we also determined non-local
parameters characteristic of CNS inflammation (presence of
oligoclonal IgG bands, and concentrations of oligoclonal and
total IgG). However, no significant correlations between metabo-
lite levels and immunoglobulin concentrations were found using
the Spearman rank test. A Mann-Whitney U test resulted in
significantly increased lactate levels for CSF samples from CIS
patients demonstrating IgG oligoclonal bands vs. patients not
showing oligoclonality, while no other metabolic differences were
found between these two classes (data not shown).
The patients’ age had no significant effects upon CSF
metabolite levels, as verified by Spearman Rank correlation.
There were no significant differences in metabolite concentrations
between women and men, except for slightly enhanced glutamine
(0.64260.035 vs. 0.53860.021) and creatinine (0.09360.003 vs.
0.08260.003) in men as evidenced by Mann-Whitney U tests
(p=0.0061 and 0.0058, respectively).
DISCUSSION
Metabolic variations and patient homogeneity
All MS patients investigated in this study belong to a highly
homogeneous population, in contrast to previously published
1H
MR studies of CSF. For the first time, solely patients presenting
the clinically isolated syndrome (CIS) were included, prior to any
MS treatment. In addition, patients were carefully monitored to
categorically exclude any possibility of interference by other (MS-
unrelated) drug treatment. We found a number of metabolic CSF
parameters differing between CIS patients with and without active
plaques, and between either patient group and controls. These
statistically significant differences are indicative of metabolic
processes underlying and/or accompanying inflammatory MS
plaques. However, CSF metabolite analysis cannot be recom-
Figure 2. Percentile plots for selected CSF metabolite concentrations [mM] in patients with or without inflammatory brain MS plaques
(abbreviated ‘inflamm’ and ‘non-inflamm’, respectively), and controls. These plots show the percentage of data less than or equal to an observed
value. Marked deviations from normal distribution are readily recognized by major deviations from a straight line. The percentile plots for fructose
illustrate the presence of CSF with particularly increased concentrations in CIS patients, independently of the presence of inflammatory plaques.
doi:10.1371/journal.pone.0000595.g002
MS Plaques and CSF Metabolites
PLoS ONE | www.plosone.org 4 July 2007 | Issue 7 | e595mended for diagnostic purposes since the metabolite concentration
ranges for the three groups overlapped considerably.
Increased b2hydroxyisobutyrate levels in CSF are
closely associated with inflammatory MS plaques
One of the most striking results of our study is the first
unambiguous detection of enhanced absolute (molar) BHIB and
lactate concentrations in CSF of MS patients with vs. without
inflammatory plaques. BHIB levels were positively correlated with
the presence, but not with the number of inflammatory plaques.
BHIB is a typical partial-degradation product of branched-chain
amino acids (primarily valine) released from muscle for hepatic
and renal gluconeogenesis [9]. The observed BHIB increase in
CSF may in fact be due to an increased uptake (leakage?) from
blood as discussed elsewhere [10], since BHIB is more concen-
trated in serum than in CSF [11,12].
Notwithstanding, some of the BHIB increase may stem from
astrocytes. Recent evidence suggests that these neural cells express
moderate glucose 6-phosphate hydrolase and transporter activities
[13], enabling gluconeogenesis and glucose release from the brain
[13,14]. Thus, increased levels of the gluconeogenesis substrate,
BHIB, in CSF may be in part the result of a perturbation of
astrocytic gluconeogenesis. The latter effect may be due to the
presence of inflammatory plaques, or due to reduced cerebral
blood flow as a result of a perturbation of microcirculation.
Impaired microcirculation in MS may also explain lactate
accumulation (see following section).
Lactate levels in CSF are correlated with the number
of inflammatory MS plaques
The statistically significant correlation between CSF lactate
concentration and the number of inflammatory plaques found in
our study (CIS group 1) clearly corroborates the assumption of
a link between lactate production and inflammatory plaques [4].
This hypothesis is further supported by the finding that an
extrapolation of the linear fit to zero inflammatory plaques yielded
virtually the same lactate concentration as CIS group 2. In fact,
lactate is a known marker of acute inflammation, although
elevated lactate levels in CSF have also been found to reflect
increased tissue acidosis and anaerobic glycolysis in other diseases
[15–17]. It has been shown that in the presence of physiological
Figure 3. Scattergrams for lactate and acetate CSF concentrations
[mM] in patients with or without inflammatory brain MS plaques
(abbreviated ‘inflamm’ and ‘non-inflamm’, respectively), and con-
trols. Marked deviations from normal distribution are readily recog-
nized for lactate (inflamm) since data are clustered at low values
(around 2.2 mM), but also for acetate (inflamm) where data are
clustered at high values (around 0.16 mM).
doi:10.1371/journal.pone.0000595.g003
Table 3. Significance of differences in CSF metabolites
between CIS patients with and without inflammatory MS
plaques and controls.
......................................................................
Mann-Whitney UFisher’s PLSD compared groups
lactate 0.0433 0.0356 inflamm. vs. noninflamm.
BHIB 0.0144 0.0127 inflamm. vs. noninflamm.
BHIB 0.0851 0.0646 inflamm. vs. control
phenylalanine 0.0836 0.0932 inflamm. vs. noninflamm.
b-glucose 0.0251 0.0069 inflamm. vs. control
glutamine 0.0384 0.0309 inflamm. vs. control
creatinine 0.0250 0.0403 inflamm. vs. control
acetate 0.0311 0.0123 inflamm. vs. control
fructose 0.0142 0.0179 inflamm. vs. control
fructose 0.0161 0.0203 noninflamm. vs. control
P values for a nonparametric (Mann-Whitney U) and a parametric (Fisher’s PLSD)
test (see Materials and Methods for details of the statistical evaluation). Bold
characters indicate significance at the p,0.05 level, while regular characters
indicate borderline significance (0.05,p,0.10). Differences between CIS
groups with (‘inflamm.’) and without (‘noninflamm.’) active MS brain plaques
were analyzed based on the concentrations presented in Figure 1 (see also
Table 2 for a summary).
doi:10.1371/journal.pone.0000595.t003
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Figure 4. Lactate concentration [mM] in CSF of CIS patients with
inflammatory plaques vs. number of inflammatory plaques, with
linear fit.
doi:10.1371/journal.pone.0000595.g004
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PLoS ONE | www.plosone.org 5 July 2007 | Issue 7 | e595stimulating factors, cultured macrophages derived from human
monocytes synthesize increased amounts of lactate from glucose
[18]. Thus, increased lactate production by immune cells is
possibly at the origin of the increased CSF lactate levels observed
in the presence of inflammatory MS plaques. Interestingly, lactate
levels exhibit a stronger correlation with the number of
inflammatory plaques than with markers of general CNS
inflammation (IgG levels, oligoclonality). This suggests inflamma-
tory plaques either directly produce lactate, or are closely linked to
processes resulting in increased lactate production and/or release
into CSF. Recent evidence suggests perturbed microcirculation in
conjunction with hypoxia-like injury during MS plaque formation
[19,20]. This finding raises the possibility of increased lactate
production by anaerobic glycolysis in and/or around emerging
plaques, in an attempt to compensate for reduced oxidative ATP
production. Some of the lactate produced in this way may be
released into the CSF and explain increased levels for CIS patients
with active plaques.
It is well established that the concentration of cerebral lactate
directly depends on its rate of production in brain, while blood and
CSF lactate concentrations are largely independent of each other
[17,21]. The lack of a correlation between lactate levels in CSF
and serum of CIS patients, as determined in our study, confirms
this finding. Note that CSF, although mainly produced in the
choroid plexus (located in the fourth and lateral brain ventricles)
and in the brain parenchyma, was sampled in the interspaces
between lumbar vertebrae. Thus, processes occurring in the spinal
canal, including also the spinal cord, may affect the results of CSF
analyses, although the occurrence of active plaques in the spinal
cord was not investigated. Another cause of lactate accumulation
would be reduced clearance from CSF, but there is no evidence
that changed lactate transport might play a significant role.
Interestingly, oligoclonality, which is a marker of general CNS
inflammation and present in 79–90% of MS patients, was less
correlated with the number of inflammatory plaques than were
lactate levels. Thus, as opposed to lactate, oligoclonality may be
more indicative of CNS inflammation not directly linked to brain
plaques (diffuse inflammation).
MS heterogeneity and lactate changes
For our pooled MS group consisting of CIS patients with and
without inflammatory plaques, no significant lactate increase was
observed vs. the control group, owing to slightly decreased values
for CIS group 2 (see Results). These findings suggest that the
outcome of a comparison of lactate levels between MS patients
and controls greatly depends on the composition of the MS cohort
involved. Obviously, the proportion of patients with numerous
active plaques plays a crucial role. However, other parameters
may also be important, such as the proportion of CIS cases vs.
cases with a history of multiple attacks, the proportion of treated
vs. untreated patients, the characteristics of the control group
chosen etc. Most certainly, CSF concentrations of metabolites
other than lactate will also depend on the specific form and stage
of MS under investigation.
Glucose CSF concentrations are increased in CIS
patients without active plaques
In contrast to lactate levels, glucose and fructose concentrations in
CSF are generally determined by blood glucose concentrations
[17]. The CSF concentration of glucose usually is about 60% of
the blood concentration [17]. Normally, glucose enters CSF
predominantly through facilitated diffusion, and follows blood
level variations with a delay of approximately four hours [17]. A
wide range of facilitating glucose transporters and isoforms have
been identified in the CNS over the past years [22]. Increased
glucose concentrations in CSF have been attributed to an
increased permeability of the blood-brain barrier. Indeed, the
Figure 5. Two-dimensional projection of a three-dimensional CSF
metabolite plot, based on the first three principal components
obtained by PCA. All control subjects (green dots) are clustered within
the broken ellipse that also contains one data point from each of the
groups with and without inflammatory plaques (red and black dots,
respectively).
doi:10.1371/journal.pone.0000595.g005
Figure 6. Two-dimensional projection of a three-dimensional CSF
metabolite plot, based on the first three principal components
obtained by PCA (projection angle changed relative to Figure 5). All
CIS patients with inflammatory plaques (red dots), except for two, are
clustered within the broken ellipse that also contains four data points
from patients without inflammatory plaques (black dots).
doi:10.1371/journal.pone.0000595.g006
MS Plaques and CSF Metabolites
PLoS ONE | www.plosone.org 6 July 2007 | Issue 7 | e595CSF protein content is generally increased in MS patients vs.
controls. This effect is commonly ascribed to a blood-brain barrier
breakdown in a section of the brain or the spinal cord during MS
attacks. Thus, the increased glucose levels found in CSF of MS
patients with active plaques may partly stem from increased
permeability of the blood-brain barrier. Since glucose is usually
more concentrated in CSF than in brain tissue, CSF is thought to
meet a part of the glucose demand of the brain by facilitated
transport across the brain-CSF barrier [17].
Fructose CSF concentrations are equally increased in
CIS patients with and without active plaques
In general, fructose levels are considerable higher in CSF than in
blood plasma [17]. While the mechanistic background of the
fructose distribution in CSF vs. blood is unknown, it has been
suggested that fructose is an end product of brain metabolism,
accounting for the CSF:plasma fructose ratio greater than unity.
In fact, a close correlation between glucose and fructose
concentrations in CSF has been established [17,23]. One glucose
transporter (GLUT5) isoform has been found to functionally serve
as a high-affinity fructose transporter [22]. The fact that fructose is
characteristically enhanced in the CSF of MS patients irrespective
of the presence of active plaques suggests enhanced transport
across the brain-CSF barrier, while decreased fructose uptake by
blood seems less likely.
Glutamine and creatinine
Glutamine is an amino acid that plays an important role in brain
metabolism. It is produced in large quantities and serves as
a precursor of glutamate, the most abundant neurotransmitter in
the CNS. However, it is also involved in numerous biosynthetic
processes of the body, and is more concentrated in blood than in
CSF. Due to substrate exchange between blood and CSF, the
origin of increased glutamine in CSF of MS patients with
inflammatory plaques vs. controls is difficult to assess. A recent
in vivo
1H MRS study suggested increased glutamate, but not
glutamine concentration in brain of MS patients [24]. Further-
more, our statistical evaluation showed that the CSF levels of
glutamine and creatinine, another compound involved in nitrogen
metabolism (e.g. in muscle protein degradation), varied signifi-
cantly between the male and female patient subpopulations. Thus,
the increased glutamine and creatinine levels found for CIS group
1 vs. controls may in part reflect the higher proportion of males in
the former (29 vs. 10%). CIS group 2 consisted of 25% males, and
their CSF glutamine and creatinine concentrations ranged
between those of controls and CIS group 1. Further metabolic
studies should be able to shed more light on the mechanisms of
changed glutamine and creatinine metabolism in MS.
Phenylalanine Phenylalanine CSF concentrations were
slightly decreased in patients with active vs. inactive plaques
(borderline significance, Tables 2 and 3). This aromatic amino
acid is a precursor of the synthesis of the catecholamines,
dopamine, noradrenaline and adrenaline [25]. Although
phenylalanine can cause brain damage when present above
a critical concentration, e.g. in phenylketonuria, it has been used,
in combination with other compounds, as an effective drug to
relieve MS symptoms. Its mechanism of action is thought to be
associated with an increased synaptic availability of the
neurotransmitter, noradrenaline, which may be depleted in MS
patients [25]. Our results suggest that minor phenylalanine
reduction in MS patients may be specifically linked to the
presence of inflammatory plaques. However, further studies need
to be carried out to test this hypothesis.
Acetate Acetate is a metabolite of N-acetylaspartate and the
neurotransmitter, acetylcholine, but is also involved, as acetyl-
CoA, in lipid and carbohydrate metabolism (entry into the citric
acid cycle). Some of us have previously reported that an
accumulation of long-chain acyl CoA could result in the
inhibition of acetyl CoA carboxylase, thereby diverting acetyl
CoA from fatty acid synthesis to acetate formation via hydrolysis
by acetyl CoA hydrolase (EC 3.1.2.2) [26]. In MS, acetate
accumulation in brain has been interpreted in terms of reduced
acetate incorporation into lipids, and the latter was suggested to
play a role in altered myelin stability seen in MS [27]. However,
the acetate decrease observed in the CSF of CIS group 1 and, to
a lesser extent, CIS group 2, does not reflect these mechanisms.
The biochemical pathways of acetate metabolism in MS await
further elucidation.
Conclusion
In clinically isolated syndrome (CIS), significantly increased
b2hydroxyisobutyrate and lactate levels were detected in CSF
of patients with vs. without active MS plaques. However, no
significant differences were detected for these metabolites when
comparing controls and CIS with or without active plaques. This
finding underlines the heterogeneity of different manifestations of
MS with respect to organic-acid metabolism. A compelling
correlation was found between lactate concentration and the
number of inflammatory plaques, suggesting a close link between
plaque activity and lactate production. Several other metabolites
(glucose, glutamine, acetate and creatinine) were found to vary
significantly between controls and the group with active plaques
only. These results contribute important elements to the in-
vestigation of metabolic processes involved in inflammatory MS
plaques, and serve to guide further mechanistic studies of specific
MS manifestations.
MATERIALS AND METHODS
Patients
All patients gave their written informed consent to participate in
this research protocol promoted by the French National Center of
Scientific Research (CNRS) before entry. This protocol had been
approved by the local Ethics Committee Marseille 1 (February 21,
2002).
A group of 33 CIS (clinically isolated syndrome suggestive of
MS) patients was recruited from the department of Neurology
(Timone Hospital, Marseille, J. Pelletier). Inclusion criteria were:
age 18 to 45 years; occurrence of a first presumed inflammatory
demyelinating event of acute onset in the central nervous system
involving the spinal cord, the hemisphere or the brain stem; no
previous history of neurological symptoms suggestive of de-
myelination; exclusion of alternative diagnoses by extensive
investigations; presence of oligoclonal banding on CSF analysis;
presence, on the initial MRI performed at time of inclusion, of one
or more brain (including optic nerve) or spinal lesions (initial MRI
included contiguous T1-weighted images with and without
gadolinium enhancement, T2-weighted images and FLAIR
images); patient not included in any other clinical trial.
Twenty-one of the CIS patients investigated showed inflamma-
tory (active) plaques at brain MRI, as indicated by Gd-DTPA
contrast-enhancement. The number of inflammatory plaques
generally ranged between 1 and 10, although in two patients, 13
and 26 inflammatory plaques were detected, respectively (ID
numbers 17 and 12, Table 1). The control group consisted of 10
patients suspected of multiple sclerosis. The average age of
controls, patients with (CIS group 1) and without (CIS group 2)
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respectively. The sex ratio F/M was 9/1 for the control group,
15/6 for CIS group 1, and 9/3 for CIS group 2. MS was
diagnosed according to McDonald’s criteria [28].
For ethical reasons, it was not possible to have lumbar puncture
performed on healthy volunteers. The control group did not
present any abnormality at routine CSF analysis (immunoglobu-
lins, B and T cells, glucose and total protein levels). Only one
control subject had medical drug treatment (not related to
inflammation) at the time of lumbar puncture, but did not show
any CSF metabolite levels outside the range of the other controls.
In general, 1 to 3 ml CSF were available for MRS analysis; in 5
cases, 340 ml to 1 ml were available. Blood and urine samples were
obtained at the time of CSF collection to test if differences in CSF
lactate concentrations were paralleled by similar differences in
serum and urine.
Detection of intrathecal IgG
For all patients, paired samples of CSF and serum were collected
under sterile conditions after lumbar and venous punctures,
respectively. Samples were stored at 280uC until free light chain
(FLC) assays. All assays were performed under identical condi-
tions. For each CSF sample, white and red blood cells were
counted by light microscopy. IgG and albumin concentrations
were quantified by immunonephelometry using a Behring ana-
lyzer (BNII, Dade Behring, Deerfield, IL). An index of the blood-
CSF barrier function was obtained by calculating a CSF/serum
albumin ratio. The IgG index and the intrathecal synthesis of IgG
(Reiber’s formula) were calculated as previously described [29].
Oligoclonal IgG banding was detected in unconcentrated fresh
CSF samples according to the commercially available immuno-
peroxidase method [29,30]. Immunofixation performs comparably
to other analytical methods such as isoelectric focusing [31].
MRS sample preparation
CSF samples were stored at 280uC following lumbar puncture.
For MRS analysis, CSF was lyophilized as described previously
[32], and the lyophilizate was redissolved in 620 mlD 2O. Sixty
microliters of a 15 mM solution of (sodium) 3-(trimethylsilyl)-
2,29,3,39-tetradeuteropropionate (TSP-d4)i nD 2O were added to
each sample for chemical shift referencing and quantitation, and
pH was adjusted with DCl and NaOD solutions to approximately
7.0. Lyophilization allowed for sample concentration up to a factor
of 4–5, depending on the initial CSF volume available. Urine and
serum samples were also stored at 280uC. Urine was lyophilized
before MRS, while serum was analyzed following ultrafiltration to
remove proteins.
MR spectroscopy
Data acquisition
1H NMR spectra at 400.1 MHz were
obtained on a 9.4 T AM-400 WB spectrometer from Bruker
(Wissembourg, France), using a quattro nucleus probe for 5-mm
tubes (tunable to
1H,
31P,
13Ca n d
19F NMR resonance
frequencies). Samples were spun at a rate of 20 Hz during NMR
measurements. A standard Bruker Eurotherm BVT-3200 variable
temperature unit was employed to maintain a sample temperature
of 28uC. Biofluids were examined using 5-mm Wilmad 528-PP
tubes (Carlo Erba-SDS, Val de Reuil, France).
1H NMR spectra
were acquired under conditions that ensured full nuclear relaxation
in all metabolites and the reference compound (pulse repetition time
TR=47.6 s, pulse width (90u)P W = 1 2 . 1 ms). Spectra were
acquired using AQ=6.56 s (64 k), preceded by water proton
presaturation for 6 s (power setting 0.001 W).
Data processing Before metabolite quantification, MR
signals were apodized (exponential multiplication using
LB=0.5 Hz), Fourier transformed, and phase and baseline
corrected. To quantitate the particularly weak aromatic amino
acid signals, apodization with LB=1.5 Hz was chosen for better
signal-to-noise ratios. Spectra were integrated using Bruker’s
MDCON deconvolution routine; a 80% Lorentzian/20%
Gaussian lineshape was found to optimally fit most metabolite
signals. Metabolite signals were quantitated as described before for
CSF of MS patients, to allow comparison with published results
[3,6]. NMR signal assignments were based on chemical-shift
values previously presented for
1H NMR spectra of CSF samples
[3,33], and on addition of original compounds to CSF (‘‘spiking’’).
BHIB was identified as described in a separate report [10].
MR imaging
All subjects were explored on a 1.5 T Magnetom Vision Plus
imager (Siemens, Erlangen, Germany). The MRI protocol
included localizer images, fast transverse SE proton density-
weighted and T2-weighted images (TE1/TE2/TR=15/85/
2600 ms; 44 contiguous slices, thickness=3 mm; flip angle=90u;
FOV=240 mm; matrix=256
2). A T1-weighted SE sequence
(TE/TR=10/650 ms, 25 contiguous slices, thickness=5 mm;
FOV=240 mm; matrix=256
2) was performed before and
5 minutes after injection of Gd-DOTA (Dotarem, Gerbet,
0.1 mM/kg). MR images were analyzed by consensus during
a single session by two observers (J.P.R. and B.A.) who were
blinded to the clinical findings. The gadolinium-enhanced T1-
weighted images were analyzed for the number of enhancing
lesions.
Statistics
Statistical tests were performed using Statview 5.0.1 software (SAS,
Cary, NC, USA). First, homogeneities of variances were examined
using F-tests, yielding equal variances for all metabolites and
patient groups compared (except for creatinine in controls vs. CIS
group 1, p=0.049). Percentile plots (Figure 2) and scatter plots
(Figure 3) were used to assess probability distributions since
commonly available normality tests have little power to tell
whether or not small sample groups are characterized by normal
distribution [34,35]. Significant deviations from normal distribu-
tion were detected for several metabolite/patient group combina-
tions (Figures 2 and 3). Because parametric tests such as analysis of
variance and linear discriminant analysis are appropriate only
where the conditions of both equal variances and normal
distribution are met, we used nonparametric tests (Spearman
rank analysis and Kruskal-Wallis/Mann-Whitney U tests) to
ascertain significant (p,0.05) correlations and differences between
groups, respectively. However, nonparametric methods such as
the Mann-Whitney U test are known to occasionally result in an
underestimation of significance in cases where the assumptions of
parametric tests apply fully or almost completely [35]. Moreover,
since the Mann-Whitney U test is not designed to test for
significance in multiple comparisons, results based on this two-
sample test were verified by employing a parametric multiple-
comparison method, Fisher’s PLSD test (a nonparametric test for
pairwise multiple comparisons was unavailable). Consistent p
values for parametric and nonparametric tests clearly support the
validity of our results (Table 3).
Principal component analysis was employed to examine
clustering of data according to patient groups (JMP, SAS, Cary,
NC, USA), using the 27 metabolite levels that were reliably
quantitated. Our PCA method, based on actual (absolute)
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currently used in metabolomic MRS. The latter relies on
intensities of spectral points or, more commonly, of ‘‘bins’’ or
‘‘buckets’’ (sums of a number of adjacent spectral points). One
crucial advantage of employing metabolite concentrations (based
on fitted peak areas) is that pattern recognition is not hampered by
intersample peak position and line width variation [36]. These
changes are the consequence of matrix effects (pH, ionic strength,
etc.). Although there are techniques to align spectra prior to
analysis, a significant limitation to these approaches is that
overlapping peaks are highly problematic [36]. In contrast,
deconvolution of overlapping peaks for metabolite quantitation
fully takes into account these variations. A further advantage of
using metabolite levels for PCA is that each of the resulting
principal components directly represents a well defined linear
combination of metabolite concentrations. On the contrary,
binning-based principal components reflect combinations of
spectral regions. Many of these are likely to represent super-
imposed MRS signals from different metabolites, while the relative
contributions of individual metabolites to each region remain
unknown.
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